For research use only. Not for therapeutic Use.
bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC50=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs[1].
bPiDDB (peripherally administered) inhibits nicotine-evoked dopamine (DA) release in nucleus accumbens and decrease intravenous nicotine self-administration in rats[1].
bPiDDB is brain bioavailable following peripheral administration and is transported actively by the blood-brain barrier choline transporter into the central compartment[1].
| Catalog Number | I010723 |
| CAS Number | 525596-66-1 |
| Synonyms | 3-methyl-1-[12-(3-methylpyridin-1-ium-1-yl)dodecyl]pyridin-1-ium;dibromide |
| Molecular Formula | C24H38Br2N2 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H38N2.2BrH/c1-23-15-13-19-25(21-23)17-11-9-7-5-3-4-6-8-10-12-18-26-20-14-16-24(2)22-26;;/h13-16,19-22H,3-12,17-18H2,1-2H3;2*1H/q+2;;/p-2 |
| InChIKey | NNPBJCAIRCFEFZ-UHFFFAOYSA-L |
| SMILES | CC1=C[N+](=CC=C1)CCCCCCCCCCCC[N+]2=CC=CC(=C2)C.[Br-].[Br-] |
| Reference | [1]. Smith AM, et al. Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochem Pharmacol. 2010 Aug 1;80(3):402-9. |
